FindTrial
Sign In

First line treatment in HIV-related diffuse large cell non Hodgkin Lymphoma at ''high risk'', including early consolidation with high dose chemotherapy and autologous peripheral blood stem cell transplantation - ND

First line treatment in HIV-related diffuse large cell non Hodgkin Lymphoma at ''high risk'', including early consolidation with high dose chemotherapy and autologous peripheral blood stem cell transplantation - ND

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2006-006047-30-IT
Enrollment
Unknown
Registered
2007-11-12
Start date
2008-10-09
Completion date
Unknown
Last updated
2016-06-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diffuse large cell lymphoma HIV infection related MedDRA version: 6.1 Level: PT Classification code 10025312

Interventions

Pharmaceutical Form: Solution for infusion INN or Proposed INN: rituximab Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500- Pharmaceutical Form: Solution for in

Sponsors

AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: -age=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: -LNH Burkitt or Lymphoblastic -IPI: 0-1 -cardiac, respiratory, hepatic, renal failure -bone marrow failure -lymphoma localized at SNC

Design outcomes

Primary

MeasureTime frame
Main Objective: complete remission, disease free survival and failure free survival;Secondary Objective: to assess toxicity of high dose chemotherapy, incidence of opportunistic and non opportunustic infections, overall survival;Primary end point(s): complete remission, disease free survival, failure free survival—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026